ImmunOs Therapeutics
Immune system-modulating technology platform for the treatment of cancer and autoimmune diseases.
7
Funding Rounds
$210.5m
Money raised
Overview
Immune system-modulating technology platform for the treatment of cancer and autoimmune diseases.
- Website:
- Business model: B2B
- Headquarters: Zürich
- Social accounts: linkedin
Funding
Funding series
Funding Series Analysis
The company ImmunOs Therapeutics has raised a total of $210.5m in funding over 7 rounds.
Key Insights:
- ImmunOs Therapeutics Series C Round, September 2024: $11m
- ImmunOs Therapeutics Series B round, June 2022: $74m
- ImmunOs Therapeutics June 2022 Funding Round: $74m
- ImmunOs Therapeutics December 2019 Series A Funding Round: $17m
- ImmunOs Therapeutics December 2019 Series A Funding Round: $17m
- ImmunOs Therapeutics Series A round, December 2019: $15m
- ImmunOs Therapeutics December 2017 Seed Funding Round: $2.5m
ImmunOs Therapeutics Series C Round, September 2024
$11m
ImmunOs Therapeutics Series B round, June 2022
$74m
ImmunOs Therapeutics June 2022 Funding Round
$74m
ImmunOs Therapeutics December 2019 Series A Funding Round
$17m
ImmunOs Therapeutics December 2019 Series A Funding Round
$17m
ImmunOs Therapeutics Series A round, December 2019
$15m
ImmunOs Therapeutics December 2017 Seed Funding Round
$2.5m
Industries
ImmunOs Therapeutics is active in the following industries: